{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lexapro+%28escitalopram%29",
    "query": {
      "intervention": "Lexapro (escitalopram)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 318,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lexapro+%28escitalopram%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T00:36:32.290Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04352101",
      "title": "Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depression"
      ],
      "interventions": [
        {
          "name": "Bupropion XL",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "25 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2020-09-23",
      "completion_date": "2022-07-25",
      "has_results": true,
      "last_update_posted_date": "2023-12-29",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04352101"
    },
    {
      "nct_id": "NCT03128021",
      "title": "Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Escitalopram Pill",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Levomilnacipran Pill",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Howard Aizenstein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2017-05-24",
      "completion_date": "2023-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-10",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03128021"
    },
    {
      "nct_id": "NCT01473381",
      "title": "Safety and Efficacy of Vilazodone in Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Vilazodone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to citalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo to vilazodone",
          "type": "DRUG"
        },
        {
          "name": "Citalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1162,
      "start_date": "2011-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-08",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01473381"
    },
    {
      "nct_id": "NCT01398865",
      "title": "Escitalopram Neuroimaging Supplement",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Body Dysmorphic Disorder"
      ],
      "interventions": [
        {
          "name": "PET scan and MRI scan",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 23,
      "start_date": "2008-12",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2015-03-13",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01398865"
    },
    {
      "nct_id": "NCT00574847",
      "title": "Responses of Myocardial Ischemia to Escitalopram Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Myocardial Ischemia"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 127,
      "start_date": "2006-09",
      "completion_date": "2011-11",
      "has_results": true,
      "last_update_posted_date": "2015-08-05",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574847"
    },
    {
      "nct_id": "NCT01364649",
      "title": "Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Treatment Outcome"
      ],
      "interventions": [
        {
          "name": "Vortioxetine",
          "type": "DRUG"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 447,
      "start_date": "2011-06",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2014-10-09",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 53,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chino",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01364649"
    },
    {
      "nct_id": "NCT06826326",
      "title": "Neuroimaging of Escitalopram in Autism Spectrum Disorder",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Escitalopram 10mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kathryn Unruh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 5,
      "start_date": "2025-04-28",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06826326"
    },
    {
      "nct_id": "NCT04623099",
      "title": "Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 132,
      "start_date": "2021-03-08",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04623099"
    },
    {
      "nct_id": "NCT03522844",
      "title": "Treatments for Anxiety: Meditation and Escitalopram",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anxiety Disorders",
        "Generalized Anxiety Disorder",
        "Panic Disorder",
        "Social Anxiety Disorder",
        "Agoraphobia"
      ],
      "interventions": [
        {
          "name": "Mindfulness-Based Stress Reduction",
          "type": "OTHER"
        },
        {
          "name": "Escitalopram",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 276,
      "start_date": "2018-06-18",
      "completion_date": "2022-01-05",
      "has_results": false,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • New York, New York",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03522844"
    },
    {
      "nct_id": "NCT00360399",
      "title": "Identifying Factors That Predict Antidepressant Treatment Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Escitalopram",
          "type": "DRUG"
        },
        {
          "name": "Duloxetine",
          "type": "DRUG"
        },
        {
          "name": "Cognitive behavioral therapy (CBT)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 344,
      "start_date": "2006-08",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-08-30",
      "last_synced_at": "2026-09-29T00:36:32.290Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00360399"
    }
  ]
}